ERBB2 and breast cancer: [36] explored the application value of a DCE‐MR Radiomics Prediction Model for identifying HER2‐low‐expressing and HER2‐positive breast cancer and distinguished HER2‐low from HER2‐positive breast cancer on the basis of dynamic contrast‐enhanced MR, which achieved an AUC of 0.87 with an accuracy of 0.80, a sensitivity of 0.89, and a specificity of 0.82.